November 10: at the Mastocytes and Basophils Club of the French Society of Immunology which is organizing its second meeting, within the Imagine Institute in Paris
November 27: 6
e
webinar of the “Naked Immunology” series organized by the company Genoskin
Suresnes, November 10, 2023 – 8:00 a.m. CET – Néovacs (Euronext Growth Paris: ALNEV), a biopharmaceutical company at a preclinical stage developing new therapies for inflammatory and autoimmune diseases, announces that work on its anti-kinoid therapeutic vaccine program IgE will be presented at two international meetings.
2
n/a
Mast Cell and Basophil Club Day
:
Presentation titled:
IgE in the pathophysiology & therapy of food allergy
Speaker: Dr. Laurent Reber, Director of Research and Innovation
18
th
International Congress of Immunology
:
Presentation titled:
Development of an anti-IgE vaccine for long-term prevention of anaphylaxis
Speaker: Dr. Laurent Reber, Director of Research and Innovation
The results of preclinical studies presented at these two conferences demonstrate that Kinoid IgE induces lasting protection against anaphylactic shock, the most severe clinical manifestation of allergy.
ABOUT NEOVACS
Néovacs is a French biotechnology company which conducts a dual activity of R&D and investment.
Its own products are vaccine candidates developed from its kinoid® technology platform in lupus and allergies. The innovative approach uses the patient’s immune system to regulate harmful overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE.
At the same time, the Company uses its internal expertise to invest in innovative Biotech and Medtech companies with high potential.
Néovacs has been listed on Euronext Growth since 2010.
For more information :
www.neovacs.fr
Jérôme FABREGUETTES LEIB | Anne-Charlotte DUDICOURT |
Warning :
The company Néovacs has set up (i) financing in the form of OCEANE-BSA with the company European High Growth Opportunities Securitization Fund, which, after receiving the shares resulting from the conversion or exercise of these instruments, n is not intended to remain a shareholder of the company, and (ii) financing in ORA which have all been transferred to a trust, which is now responsible for their equitization.
The shares resulting from the conversion or exercise of the above-mentioned securities are generally sold in the market at very short notice, which can create strong downward pressure on the share price. In the specific case of the trust, the shares are sold on the market according to the terms set out in the trust agreement.
Shareholders may suffer a loss of their invested capital due to a significant decrease in the value of the company’s stock, as well as significant dilution due to the number of securities issued to the company European High Growth Opportunities Securitization Fund and/or trust.
Investors are advised to be very vigilant before making the decision to invest (or remain invested) in the securities of the company admitted to trading which carries out such dilutive financing transactions, particularly when they are carried out successively. The company recalls that this dilutive financing operation is not the first that it has implemented.
This publication has the “🔒 Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
mJufk5xnZpjKymxwacaYamKXmZdpxWbImmPGxGlpZZ3JZ3GUmpdjaJnGZnFjnWps
– To control this key:
https://www.security-master-key.com.
Regulated information:
Inside information:
– Other press releases
Full and original press release in PDF format:
https://www.actusnews.com/news/82856-2023.11.09_nvcs_cp_congres2_vfinal.pdf
© Copyright Actusnews Wire
Receive future company press releases free of charge by email by subscribing to www.actusnews.com